Actinium Pharmaceuticals starts patient enrollment in pan‑cancer RADIANZ imaging trial
Actinium Pharmaceuticals announced that its RADIANZ imaging study is now enrolling patients with advanced solid tumors. The trial uses ⁸⁹Zr‑Barecetamab‑DFO PET imaging to assess biodistribution, tumor uptake, pharmacokinetics and dosimetry of the HER3‑targeting radiotherapy ATNM‑400. It includes cohorts with non‑small cell lung, breast, colorectal, pancreatic and ovarian cancers. CEO Sandesh Seth said dosing the first patient marks a major step in the company’s pan‑cancer strategy.
Why it matters
Actinium says the trial will provide data to guide ATNM‑400’s development across multiple HER3‑expressing cancers, potentially expanding the product’s market beyond prostate cancer.
Key facts
- 1The RADIANZ imaging trial began enrolling patients as announced on November 11, 2026. prnewswire.com
- 2The study evaluates ⁸⁹Zr‑Barecetamab‑DFO PET imaging to guide development of ATNM‑400 in solid tumors beyond prostate cancer. investing.com
- 3Patients with non‑small cell lung, breast, colorectal, pancreatic and ovarian cancers who have progressed on standard‑of‑care therapy are eligible. investing.com
- 4In the earlier Phase 1 prostate cancer study, the first three patients received ATNM‑400 at 1.0 µCi/kg with no dose‑limiting toxicities. prnewswire.com
- 5Dose escalation in that study advanced to 1.5 µCi/kg. investing.com
- 6Sandesh Seth, Actinium’s Chairman and CEO, called dosing the first RADIANZ patient a major step in the pan‑cancer strategy. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.